{"id":54410,"date":"2026-01-16T20:06:25","date_gmt":"2026-01-16T12:06:25","guid":{"rendered":"https:\/\/flcube.com\/?p=54410"},"modified":"2026-01-16T20:06:26","modified_gmt":"2026-01-16T12:06:26","slug":"zelgens-zggs18-zg005-cleared-by-nmpa-for-advanced-solid-tumor-studies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54410","title":{"rendered":"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved clinical studies for <strong>ZGGS18<\/strong> and <strong>ZG005<\/strong> in combination with chemotherapy for <strong>advanced solid tumors<\/strong>, advancing two <strong>Category\u202f1 biologics<\/strong> with novel mechanisms into human trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Suzhou Zelgen Biopharmaceuticals (688266.SH)<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>ZGGS18 (VEGF\/TGF\u2011\u03b2 trap) and ZG005 (PD\u20111\/TIGIT bispecific)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Clinical Trial Application (CTA)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors (combination with chemotherapy)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>14\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Phase\u202fI\/II dose\u2011escalation and expansion<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First dual\u2011functional VEGF\/TGF\u2011\u03b2 trap; PD\u20111\/TIGIT bispecific for solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>ZGGS18 (VEGF\/TGF\u2011\u03b2 Dual\u2011Functional Fusion Protein):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Binds <strong>VEGF<\/strong> to inhibit tumor angiogenesis<\/li>\n\n\n\n<li><strong>Traps TGF\u2011\u03b2<\/strong> to suppress immunosuppressive tumor microenvironment and reduce metastasis<\/li>\n\n\n\n<li><strong>Synergistic effect:<\/strong> Addresses both <strong>vascularization<\/strong> and <strong>immune evasion<\/strong> pathways<\/li>\n<\/ul>\n\n\n\n<p><strong>ZG005 (PD\u20111\/TIGIT Bispecific Antibody):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Blocks <strong>PD\u20111\/PD\u2011L1<\/strong> immune checkpoint<\/li>\n\n\n\n<li>Inhibits <strong>TIGIT<\/strong>, a secondary checkpoint that limits NK and T\u2011cell function<\/li>\n\n\n\n<li><strong>Dual checkpoint blockade<\/strong> enhances anti\u2011tumor immunity in solid tumors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Advanced Solid Tumor Patients (2026E)<\/strong><\/td><td>1.8\u202fmillion<\/td><td>7.5\u202fmillion<\/td><\/tr><tr><td><strong>VEGF\/TGF\u2011\u03b2 Targetable Population<\/strong><\/td><td>720,000<\/td><td>3.0\u202fmillion<\/td><\/tr><tr><td><strong>PD\u20111\/TIGIT Eligible Patients<\/strong><\/td><td>900,000<\/td><td>3.8\u202fmillion<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a545\u202fbillion<\/td><td>$32\u202fbillion<\/td><\/tr><tr><td><strong>ZGGS18\/ZG005 Peak Revenue (2032E)<\/strong><\/td><td>\u00a56.2\u202fbillion<\/td><td>$4.1\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>VEGF\/TGF\u2011\u03b2:<\/strong> Bintrafusp alfa (GSK\/Merck KGaA) \u2013 <strong>failed Phase\u202fIII<\/strong>; ZGGS18\u2019s <strong>fusion protein design<\/strong> may offer <strong>improved safety<\/strong><\/li>\n\n\n\n<li><strong>PD\u20111\/TIGIT:<\/strong> Tiragolumab (Roche) \u2013 <strong>failed lung cancer trials<\/strong>; Vibostolimab (Merck) \u2013 <strong>Phase\u202fII<\/strong>; ZG005\u2019s <strong>bispecific format<\/strong> could <strong>overcome prior failures<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Zelgen\u2019s <strong>Suzhou facility<\/strong> (capacity 10,000\u202fL) will produce both assets for clinical trials; commercial scale\u2011up planned for 2028<\/li>\n\n\n\n<li><strong>Clinical Speed:<\/strong> NMPA\u2019s <strong>Category\u202f1 biologic fast\u2011track<\/strong> enables <strong>Phase\u202fI initiation in Q2\u202f2026<\/strong> and potential <strong>conditional approval by 2029<\/strong><\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Co\u2011development of ZGGS18 and ZG005 allows for <strong>potential triple\u2011combination regimen<\/strong> (VEGF\/TGF\u2011\u03b2 + PD\u20111\/TIGIT + chemotherapy)<\/li>\n\n\n\n<li><strong>Pipeline Value:<\/strong> Validates Zelgen\u2019s <strong>bispecific and fusion protein platforms<\/strong> for next\u2011generation oncology assets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and competitive positioning for ZGGS18 and ZG005. Actual results may differ due to clinical trial outcomes, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688266_20260116_Q7UW.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20260116_Q7UW.\"><\/object><a id=\"wp-block-file--media-a3574144-9149-497f-a36d-ca2c8c6c8af1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688266_20260116_Q7UW.pdf\">688266_20260116_Q7UW<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688266_20260116_Q7UW.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a3574144-9149-497f-a36d-ca2c8c6c8af1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,29,905,246],"class_list":["post-54410","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical studies for ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors, advancing two Category\u202f1 biologics with novel mechanisms into human trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54410\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical studies for ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors, advancing two Category\u202f1 biologics with novel mechanisms into human trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54410\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T12:06:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-16T12:06:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54410#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54410\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies\",\"datePublished\":\"2026-01-16T12:06:25+00:00\",\"dateModified\":\"2026-01-16T12:06:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54410\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54410#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54410\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54410\",\"name\":\"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-16T12:06:25+00:00\",\"dateModified\":\"2026-01-16T12:06:26+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical studies for ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors, advancing two Category\u202f1 biologics with novel mechanisms into human trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54410#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54410\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54410#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical studies for ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors, advancing two Category\u202f1 biologics with novel mechanisms into human trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54410","og_locale":"en_US","og_type":"article","og_title":"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical studies for ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors, advancing two Category\u202f1 biologics with novel mechanisms into human trials.","og_url":"https:\/\/flcube.com\/?p=54410","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-16T12:06:25+00:00","article_modified_time":"2026-01-16T12:06:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54410#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54410"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies","datePublished":"2026-01-16T12:06:25+00:00","dateModified":"2026-01-16T12:06:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54410"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Combination therapy","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54410#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54410","url":"https:\/\/flcube.com\/?p=54410","name":"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-16T12:06:25+00:00","dateModified":"2026-01-16T12:06:26+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical studies for ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors, advancing two Category\u202f1 biologics with novel mechanisms into human trials.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54410#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54410"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54410#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen\u2019s ZGGS18 &amp; ZG005 Cleared by NMPA for Advanced Solid Tumor Studies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54410"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54410\/revisions"}],"predecessor-version":[{"id":54413,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54410\/revisions\/54413"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}